MT
Misbah Tahir
Chief Financial Officer

Misbah Tahir insider trades: IGM Biosciences (IGMS) stock sales

Chief Financial Officer, IGM Biosciences Last trade Jul 23, 2025 29 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2022
2
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Misbah reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 23, 2025IGMS↓ Sell$11K
Jun 16, 2025IGMS↓ Sell$2K
Mar 14, 2025IGMS↓ Sell$9K
Dec 16, 2024IGMS↓ Sell$13K
Sep 13, 2024IGMS↓ Sell$17K
Jun 14, 2024IGMS↓ Sell$12K
Mar 14, 2024IGMS↓ Sell$54K
Nov 27, 2023IGMS↓ Sell$7K
May 23, 2023IGMS↓ Sell$15K
Mar 14, 2023IGMS↓ Sell$33K
Dec 19, 2022IGMS↓ Sell$119K
Nov 23, 2022IGMS↓ Sell$19K
May 26, 2022IGMS↓ Sell$16K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Misbah Tahir's insider trades

Misbah Tahir is Chief Financial Officer at IGM Biosciences (IGMS). Since May 26, 2022, Misbah has reported no open-market purchases and 13 sales worth $328K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (17 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IGMS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.